Request Demo
Last update 17 Jan 2026
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center)
Last update 17 Jan 2026
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms- |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD22 modulators(CD22 modulators) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center)NCT04029038
Phase I/II Study of Dual CD19-CD22 Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced CD19+ CD22+ Lymphoid Malignancies
100 Clinical Results associated with Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center)
Login to view more data
100 Translational Medicine associated with Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center)
Login to view more data
100 Patents (Medical) associated with Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center)
Login to view more data
100 Deals associated with Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD19 Expressing Malignancies | Phase 2 | United States | 15 May 2019 | |
| Chronic lymphocytic leukaemia refractory | Phase 2 | United States | 15 May 2019 | |
| Non-Hodgkin's lymphoma refractory | Phase 2 | United States | 15 May 2019 | |
| Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | United States | 15 May 2019 | |
| Recurrent Chronic Lymphoid Leukemia | Phase 2 | United States | 15 May 2019 | |
| Recurrent Non-Hodgkin Lymphoma | Phase 2 | United States | 15 May 2019 | |
| Refractory B Acute Lymphoblastic Leukemia | Phase 2 | United States | 15 May 2019 | |
| Residual Neoplasm | Phase 2 | United States | 15 May 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free